CBS 2019
CBSMD教育中心
中 文

Acute Coronary Syndrom

Abstract

Recommended Article

SCAI Clinical Expert Consensus Statement on Cardiogenic Shock Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II Trial Transition of Macrophages to Fibroblast-Like Cells in Healing Myocardial Infarction Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization Complete Versus Culprit-Only Lesion Intervention in Patients With Acute Coronary Syndromes Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment The EARLY Randomized Trial SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019 No causal effects of plasma homocysteine levels on the risk of coronary heart disease or acute myocardial infarction: A Mendelian randomization study

Clinical Trial2020 Nov 7;41(42):4114-4123.

JOURNAL:Eur Heart J. Article Link

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial

J Tuñón, PG Steg, ODYSSEY OUTCOMES Investigators et al. Keywords: chronic kidney disease; glomerular filtration rate; Low-density lipoprotein cholesterol; MACE; PCSK9 inhibition

Full Text PDF